Sencilia, an early-stage Deeptech/MedTech startup, is a spin-off from the Bioinspired MEMS and Biomedical Devices (BMBD) group at the University of Groningen. Dr. Amar M. Kamat (former postdoc in BMBD and currently the CEO of Sencilia) and Prof. Ajay G.P. Kottapalli (Associate Professor and Chair of the BMBD group) founded Sencilia in Sep 2021 in order to utilize and valorize the extensive knowhow in sensor technology and nanofabrication generated within the BMBD group over many years.
Sencilia aims to enhance the safety of IV infusion therapy, and harbors the vision of becoming the standard of care in IV drug administration by 2030.
Currently at a design/development stage (TRL = 4), we're partnering with world-renowned hospitals such as Erasmus MC and UMCG to co-develop our product, and are aiming for a market launch in 2026. Join us on this exciting journey as we revolutionize IV infusion monitoring technology!
Sencilia is selected to join imec.istart.nl, a world-leading accelerator program for tech startups
Sencilia successfully completes the Venture Challenge program organized by life sciences@work, NWO and Health Holland
The SmartInfuus project (led by Sencilia in collaboration with the UMCG and University of Groningen) is awarded the SNN Valorisatie 2022 subsidy (€321k) by the European Regional Development Funds (ERDF) to perform preclinical validation of its technology
Sencilia is awarded the NWO Take-off 2 subsidy (€250k) as early-stage financing (vroegfasefinanciering) to continue its technology and business development
Sencilia is selected as one of the winners of the Academic Startup Competition 2024 organized by TeachLeapNL
